Core Points - Invivyd, Inc. announced a public offering of 74,811,404 shares of common stock at $0.52 per share, along with pre-funded warrants for 21,342,442 shares at $0.5199 each, aiming for gross proceeds of approximately $50 million [1][3] - The offering is expected to close on or about August 22, 2025, subject to customary closing conditions [1] - Cantor is acting as the sole book-running manager for the offering [2] Use of Proceeds - The net proceeds will be utilized for trial protocol development and advancement of the VYD2311 clinical program, research and development for pipeline programs including RSV and measles, and efforts related to monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome [3] Company Overview - Invivyd, Inc. is a biopharmaceutical company focused on protection against serious viral infectious diseases, starting with SARS-CoV-2, and has a proprietary technology platform for developing antibodies [7]

Core Viewpoint - Invivyd, Inc. has initiated an underwritten public offering of its common stock, with an option for underwriters to purchase an additional 15% of the shares sold at the public offering price [1][3]. Group 1: Offering Details - The offering is subject to market conditions and there is no assurance regarding its completion or the actual size and terms [1]. - Cantor is acting as the sole book-running manager for the offering [2]. - The offering will be conducted under a shelf registration statement filed with the SEC, which was declared effective on October 5, 2022 [4]. Group 2: Use of Proceeds - Invivyd plans to use the net proceeds from the offering for trial protocol development, advancement of the VYD2311 clinical program, and research related to its pipeline programs, including RSV and measles [3]. - Additional uses of the proceeds include efforts related to monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome, as well as general corporate purposes [3]. Group 3: Company Background - Invivyd, Inc. is a biopharmaceutical company focused on providing protection against serious viral infectious diseases, starting with SARS-CoV-2 [7]. - The company utilizes a proprietary technology platform to develop and adapt antibodies, and received emergency use authorization for a monoclonal antibody in March 2024 [7].

Core Viewpoint - SPX Technologies, Inc. has announced a public offering of 2,659,575 shares of its common stock at a price of $188.00 per share, aiming to raise approximately $500 million in gross proceeds before expenses [1]. Group 1: Offering Details - The offering consists of shares sold entirely by SPX, with an additional 30-day option for underwriters to purchase up to 398,936 additional shares [1]. - The expected closing date for the offering is around August 14, 2025, pending customary closing conditions [1]. Group 2: Underwriters - BofA Securities, J.P. Morgan, and Wells Fargo Securities are serving as joint book-running managers for the offering [2]. - TD Cowen and Truist Securities are also acting as book-running managers, with several other firms participating as co-managers [2]. Group 3: Regulatory Information - The shares are being offered under an effective automatic shelf registration statement previously filed with the U.S. Securities and Exchange Commission (SEC) [3]. - A prospectus supplement and accompanying prospectus will be filed with the SEC and made available on their website [3]. Group 4: Company Overview - SPX Technologies, Inc. is a diversified global supplier of engineered products and technologies, with a strong presence in the HVAC and detection and measurement markets [5]. - The company is headquartered in Charlotte, North Carolina, and employs over 4,300 people across more than 16 countries [5].

Core Viewpoint - Ramaco Resources, Inc. successfully closed a public offering of Class A common stock, raising approximately $200 million to fund its development projects and strategic growth opportunities [1][3]. Group 1: Offering Details - The company sold 10,666,667 shares of Class A common stock at a price of $18.75 per share, resulting in gross proceeds of around $200 million before expenses [1]. - Yorktown Energy Partners, as selling stockholders, granted underwriters a 30-day option to purchase additional shares worth up to $30 million, which was fully exercised [2]. - The sale of additional shares is expected to be completed on August 8, 2025, with no proceeds going to the company from this sale [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to accelerate the development of the company's rare earth elements and critical minerals project, as well as for strategic growth opportunities and general corporate purposes [3]. Group 3: Company Overview - Ramaco Resources operates in southern West Virginia and southwestern Virginia, focusing on high-quality metallurgical coal and developing rare earth and critical minerals in Wyoming [6]. - The company has four active metallurgical coal mining complexes and is in the initial stages of production for a rare earth and coal mine in Wyoming, where a significant deposit of primary magnetic rare earths was discovered [6].

Core Viewpoint - Oriental Rise Holdings Limited is conducting a public offering of up to 14,800,000 Units at a price of US$0.4681 per Unit, aiming to raise approximately US$6.9 million for various corporate purposes [1][2]. Group 1: Offering Details - The Offering consists of Units that include one Ordinary Share and one Common Warrant, with the Common Warrant exercisable at the same price as the Unit [1]. - The Common Warrants will have a downward adjustment in exercise price to 70% and 50% of the initial price on the 5th and 10th trading days post-closing, respectively [1]. - The Offering is expected to close on July 23, 2025, subject to customary closing conditions [2]. Group 2: Use of Proceeds - Proceeds from the Offering will be allocated for general corporate purposes, working capital, sales network expansion, and production capacity enhancement [2]. Group 3: Company Overview - Oriental Rise Holdings Limited is an integrated supplier of white and black tea products in mainland China, with operations covering cultivation, processing, and sales [6]. - The company operates tea gardens in Zherong County, Ningde City, Fujian Province, focusing on both wholesale and retail markets [6].

Core Viewpoint - OceanPal Inc. has announced the pricing of its upsized public offering of 10,975,600 units at a price of US$1.64 per unit, aiming to raise approximately US$18.0 million before expenses [1][3]. Group 1: Offering Details - Each unit in the offering consists of one common share and one warrant to purchase one common share [1]. - The warrants will expire three years from issuance and are immediately exercisable at an initial price equal to 225% of the public offering price, with adjustments on specified reset dates [2]. - The offering is expected to close on July 22, 2025, pending customary closing conditions [3]. Group 2: Company Overview - OceanPal Inc. is a global provider of shipping transportation services, focusing on the ownership and operation of dry bulk vessels and product tankers [6]. - The company specializes in the seaborne transportation of bulk commodities such as iron ore, coal, and grain, as well as refined petroleum products [6]. - OceanPal's fleet primarily operates on time charter trips with short to medium durations and spot charters, aiming to maximize long-term shareholder value [6].

Core Viewpoint - Civista Bancshares, Inc. has announced a public offering of 3,294,120 common shares priced at $21.25 per share, aiming for an aggregate amount of $70.0 million, with an option for underwriters to purchase an additional 494,118 shares [1][2]. Group 1: Offering Details - The gross proceeds from the offering are expected to be approximately $70.0 million before discounts and expenses, potentially increasing to $80.5 million if the underwriters fully exercise their option [2]. - The offering is anticipated to close on July 14, 2025, subject to customary closing conditions [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for general corporate purposes, which may include supporting organic growth opportunities and future strategic transactions [2]. Group 3: Management and Registration - Piper Sandler & Co. is the sole book-running manager for the offering, with several firms serving as co-managers [3]. - Civista has filed a shelf registration statement with the SEC, including a preliminary prospectus supplement for the offering [4]. Group 4: Company Overview - Civista Bancshares, Inc. is a financial services holding company with assets of $4.1 billion, headquartered in Sandusky, Ohio, and operates 42 locations across Ohio, Southeastern Indiana, and Northern Kentucky [6].

Core Viewpoint - INOVIO Pharmaceuticals, Inc. has announced a public offering of 14,285,715 shares of common stock and accompanying Series A and Series B warrants, priced at $1.75 per share, aiming to raise approximately $25 million before expenses [1][2]. Group 1: Offering Details - The public offering includes 14,285,715 shares of common stock and warrants to purchase an equal number of shares at an exercise price of $1.75 [1]. - The offering is expected to close on or about July 7, 2025, pending customary closing conditions [1]. - Underwriters have a 30-day option to purchase up to 2,142,857 additional shares and warrants at the public offering price [1]. Group 2: Financial Aspects - Gross proceeds from the offering are anticipated to be approximately $25 million, excluding underwriting discounts and commissions [2]. - The offering is being managed by Piper Sandler & Co. as the sole active book-running manager, with Oppenheimer & Co. Inc. as a passive bookrunner [2]. Group 3: Regulatory Information - A shelf registration statement for the offering was filed with the SEC on November 9, 2023, and was declared effective on January 31, 2024 [3]. - The offering is conducted through a written prospectus and prospectus supplement available on the SEC's website [3]. Group 4: Company Overview - INOVIO is focused on developing and commercializing DNA medicines aimed at treating HPV-related diseases, cancer, and infectious diseases [5]. - The company's technology is designed to optimize the design and delivery of DNA medicines that enable the body to produce its own disease-fighting tools [5].

Group 1 - Dyne Therapeutics, Inc. announced a public offering of 24,242,425 shares of common stock at a price of $8.25 per share, aiming for gross proceeds of $200 million before expenses [1] - The offering is expected to close around July 2, 2025, pending customary closing conditions [1] - Dyne has granted underwriters a 30-day option to purchase an additional 3,636,363 shares at the public offering price [1] Group 2 - The offering is conducted under a shelf registration statement filed with the SEC on March 5, 2024, which became effective upon filing [3] - A preliminary prospectus supplement has been filed with the SEC, and a final prospectus will also be filed [3] Group 3 - Dyne Therapeutics focuses on developing therapeutics for genetically driven neuromuscular diseases, including myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) [5] - The company is also advancing preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease [5]

Core Viewpoint - TAT Technologies Ltd. has successfully completed an underwritten public offering of 4,150,000 ordinary shares, with an additional 622,500 shares purchased by underwriters, raising a total of $6.3 million for general corporate purposes [1][2]. Group 1: Offering Details - The offering consisted of 1,625,000 ordinary shares sold and issued by TAT and 2,525,000 ordinary shares sold by selling shareholders [1]. - The underwriters exercised their option to purchase an additional 622,500 ordinary shares at a public offering price of $26.00 per share, the same as the initial offering price [1]. - The total gross proceeds from the sale of the Option Shares to TAT was $6.3 million, which will be used for general corporate purposes, including working capital and capital expenditures [2]. Group 2: Management and Regulatory Information - Stifel, Nicolaus & Company, Incorporated and Truist Securities, Inc. acted as joint book-running managers for the offering, with additional support from The Benchmark Company, LLC and Lake Street Capital Markets, LLC [3]. - A registration statement on Form F-3 related to the ordinary shares sold in the offering has been filed with the U.S. Securities and Exchange Commission and was declared effective on April 25, 2025 [4]. Group 3: Company Overview - TAT Technologies Ltd. is a leading provider of solutions and services to the aerospace and defense industries, operating four operational units focused on OEM and MRO services for heat transfer solutions and aviation components [6].